Non-alcoholic fatty liver disease and the gut microbiota in adolescents: is there a relationship?

Abstract Background Despite the increasing prevalence of nonalcoholic fatty liver disease (NAFLD), the pathophysiology is still not fully understood. Recent evidence suggests that the gut microbiota may play a role in the pathophysiology of NAFLD and may also offer new therapeutic options. Methods T...

Full description

Bibliographic Details
Published in:	BMC Pediatrics
Main Authors:	Doaa El Amrousy, Heba El Ashry, Sara Maher, Yousef Elsayed, Samir Hasan
Format:	Article
Language:	English
Published:	BMC 2024-11-01
Subjects:	Adolescents Metabolic dysfunction–associated steatotic liver disease Gut microbiota
Online Access:	https://doi.org/10.1186/s12887-024-05268-y

Similar Items

Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease
by: Huaying Wu, et al.
Published: (2025-12-01)

Unraveling the link between metabolic dysfunction-associated steatotic liver disease and osteoporosis: a bridging function of gut microbiota
by: Jing Zhang, et al.
Published: (2025-04-01)

Interventions targeting the gut-liver axis: A potential treatment strategy for metabolic dysfunction-associated steatotic liver disease
by: Pingping Jin, et al.
Published: (2025-07-01)

Targeting the Adipose Tissue–Liver–Gut Microbiota Crosstalk to Cure MASLD
by: Daniela Gabbia, et al.
Published: (2023-11-01)

Gut microbiota in liver diseases: initiation, development and therapy
by: Jian-Xiu Yu, et al.
Published: (2025-06-01)

The association between gut microbiota and metabolic dysfunction-associated steatotic liver disease (MASLD): a case-control study
by: Pejman Rohani, et al.
Published: (2025-10-01)

Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites
by: Dongliang Chen, et al.
Published: (2024-04-01)

From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease
by: Mi Zhou, et al.
Published: (2025-01-01)

Association of the dietary index for gut microbiota and dietary inflammation index with metabolic dysfunction-associated steatotic liver disease and metabolic alcohol-associated liver disease
by: Wenhao Wu, et al.
Published: (2025-07-01)

Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives
by: Wenchu Qian, et al.
Published: (2025-06-01)

Gut microbiota modulation by Traditional Chinese Medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease
by: Ting Zhou, et al.
Published: (2025-06-01)

From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease
by: Andrea Pasta, et al.
Published: (2025-01-01)

Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial
by: Yufeng Jin, et al.
Published: (2024-08-01)

Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease
by: In-gyu Park, et al.
Published: (2024-07-01)

Interaction mechanism and intervention strategy between metabolic dysfunction-associated steatotic liver disease and intestinal microbiota
by: Wentai Yang, et al.
Published: (2025-09-01)

MIND diet score and its association with metabolic dysfunction-associated steatotic liver disease and gut microbiota profiles: a cross-sectional study
by: Shengbo Yang, et al.
Published: (2025-08-01)

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options
by: Natalia G. Vallianou, et al.
Published: (2024-06-01)

Interplay of Oxidative Stress, Gut Microbiota, and Nicotine in Metabolic-Associated Steatotic Liver Disease (MASLD)
by: Irene Mignini, et al.
Published: (2024-12-01)

Association between the dietary index for gut microbiota and all-cause/cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease
by: Wenhao Wu, et al.
Published: (2025-07-01)

Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation
by: Byeong Hyun Min, et al.
Published: (2024-12-01)

Multi-omics integration reveals the impact of mediterranean diet on hepatic metabolism and gut microbiota in mice with metabolic dysfunction-associated steatotic liver disease
by: Zixuan Wang, et al.
Published: (2025-08-01)

Metagenome of Gut Microbiota of Children With Nonalcoholic Fatty Liver Disease
by: Yuzhen Zhao, et al.
Published: (2019-12-01)

Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD
by: Fabrizio Termite, et al.
Published: (2025-01-01)

Alterations of the duodenal mucosal microbiome in patients with metabolic dysfunction-associated steatotic liver disease
by: Mengting Ren, et al.
Published: (2024-04-01)

Phocaeicola dorei ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
by: Jieun Choi, et al.
Published: (2025-12-01)

Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease
by: Rachmad Anres Dongoran, et al.
Published: (2023-01-01)

The Role of "Biotics" in the Modulation of the Intestinal Microbiota in Metabolic-Associated Steatotic Liver Disease
by: G. Fadieienko, et al.
Published: (2025-03-01)

Early‐life antibiotic exposure aggravates hepatic steatosis through enhanced endotoxemia and lipotoxic effects driven by gut Parabacteroides
by: Xi Zhang, et al.
Published: (2025-03-01)

Adolescent alcohol drinking interaction with the gut microbiome: implications for adult alcohol use disorder
by: Bruk Getachew, et al.
Published: (2024-01-01)

Gut microbiota and nonalcoholic fatty liver disease
by: Boyeon Kim, et al.
Published: (2023-09-01)

Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Current Pathogenic Paradigm and Therapeutic Aspect
by: Ummi Maimunah, et al.
Published: (2023-11-01)

Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial
by: Doaa El Amrousy, et al.
Published: (2018-01-01)

Dysbiosis of gut microbiota after cholecystectomy is associated with non‐alcoholic fatty liver disease in mice
by: Qihan Wang, et al.
Published: (2021-08-01)

Gut Microbiota as Emerging Players in the Development of Alcohol-Related Liver Disease
by: Wei Li, et al.
Published: (2024-12-01)

Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value
by: Luyu Wang, et al.
Published: (2025-07-01)

Efficacy of Jiuzao polysaccharides in ameliorating alcoholic fatty liver disease and modulating gut microbiota
by: Qing Li, et al.
Published: (2024-02-01)

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges
by: Ernesto Saenz, et al.
Published: (2024-09-01)

The Role of Gut Microbiota—Gut—Brain Axis in Perioperative Neurocognitive Dysfunction
by: Jian Lu, et al.
Published: (2022-06-01)

Gut microbiome in non-alcoholic fatty liver disease
by: Anastasios Mpountouridis, et al.
Published: (2025-01-01)

Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies
by: Marta Maestri, et al.
Published: (2023-02-01)